Cormac Cosgrove
Overview
Explore the profile of Cormac Cosgrove including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chang C, Emberley E, DSouza A, Zhao W, Cosgrove C, Parrish K, et al.
Blood
. 2024 May;
144(7):757-770.
PMID: 38701407
Glucocorticoids are key components of the standard-of-care treatment regimens for B-cell malignancy. However, systemic glucocorticoid treatment is associated with several adverse events. ABBV-319 is a CD19-targeting antibody-drug conjugate engineered to...
2.
Touni A, Sohn R, Cosgrove C, Shivde R, Dellacecca E, Abdel-Aziz R, et al.
Pigment Cell Melanoma Res
. 2024 Mar;
37(5):583-596.
PMID: 38439216
Oral neomycin administration impacts the gut microbiome and delays vitiligo development in mice, and topical antibiotics may likewise allow the microbiome to preserve skin health and delay depigmentation. Here, we...
3.
Kosche C, Jaishankar D, Cosgrove C, Ramesh P, Hong S, Li L, et al.
JID Innov
. 2023 Aug;
3(5):100190.
PMID: 37554516
Checkpoint inhibitors treat a variety of tumor types with significant benefits. Unfortunately, these therapies come with diverse adverse events. Skin rash is observed early into treatment and might serve as...
4.
Chervin A, Stone J, Konieczna I, Calabrese K, Wang N, Haribhai D, et al.
Mol Cancer Ther
. 2023 Jun;
22(8):903-912.
PMID: 37294945
CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to a CD3 binding domain, function by bridging target-positive tumors and CD3-expressing effector T cells enabling redirected T cell-mediated...
5.
Jaishankar D, Cosgrove C, Ramesh P, Mahon J, Shivde R, Dellacecca E, et al.
Cell Stress Chaperones
. 2021 Sep;
26(5):845-857.
PMID: 34542825
Developing immunosuppressive therapies for autoimmune diseases comes with a caveat that immunosuppression may promote the risk of developing other conditions or diseases. We have previously shown that biolistic delivery of...
6.
Mukhatayev Z, Dellacecca E, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, et al.
Front Immunol
. 2020 Dec;
11:581433.
PMID: 33335528
Vitiligo is an autoimmune skin disease characterized by melanocyte destruction. Regulatory T cells (Tregs) are greatly reduced in vitiligo skin, and replenishing peripheral skin Tregs can provide protection against depigmentation....
7.
Jaishankar D, Cosgrove C, Deaton R, Le Poole I
J Vis Exp
. 2020 Apr;
(157).
PMID: 32281983
Multispectral fluorescence imaging on formalin-fixed paraffin-embedded (FFPE) tissues enables the detection of multiple markers in a single tissue sample that can provide information about antigen coexpression and spatial distribution of...
8.
Han F, Dellacecca E, Barse L, Cosgrove C, Henning S, Ankney C, et al.
Am J Respir Cell Mol Biol
. 2020 Feb;
62(6):793-804.
PMID: 32078336
Patients with lymphangioleiomyomatosis (LAM) develop pulmonary cysts associated with neoplastic, smooth muscle-like cells that feature neuroendocrine cell markers. The disease preferentially affects premenopausal women. Existing therapeutics do not cure LAM....
9.
Dellacecca E, Cosgrove C, Mukhatayev Z, Akhtar S, Engelhard V, Rademaker A, et al.
J Invest Dermatol
. 2019 Sep;
140(3):676-687.e6.
PMID: 31472106
Vitiligo is impacted by environmental triggers. We studied the contribution of the microbiome in FH mice, in which depigmentation is mediated by tyrosinase-reactive T cells. The mice received oral antibiotics...
10.
Cosgrove C, Dellacecca E, van den Berg J, Haanen J, Nishimura M, Le Poole I, et al.
J Immunother Cancer
. 2019 Jul;
7(1):186.
PMID: 31307533
Tumor immunotherapy using gene-modified T cells has already met with considerable success in the treatment of metastatic melanoma and B cell lymphoma. With improving patient prognoses, new questions arise. In...